SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
- 38 Downloads
Summary
Purpose: To evaluate the activity and toxicity of SarCNU, an oral chloroethylnitrosourea in patients with recurrent or metastatic colorectal cancer who have progressed after first-line chemotherapy. Patients and Methods: Eighteen patients with recurrent or metastatic colorectal cancer following first-line chemotherapy were treated with SarCNU 860 mg/m2 orally day 1, 5 and 9 every 6 weeks. The patient’s median age was 64 and the ECOG performance status was 0 in six, 1 in eleven and 2 in one patients. All patients were evaluable for toxicity and 16 were evaluable for response. Results: There were no objective responses (0%). One patient had stable disease and 15 had progressive disease at their first follow-up assessment. Median survival was 7.36 months (3.75–7.49 95% C.I). Neutropenia and thrombocytopenia were the most severe toxicities (grade 3-4 in six and nine patients respectively). Pulmonary toxicity was also seen in five patients who had a drop of DLCO grade from baseline and two patients who had a fall in FVC from baseline. Conclusions: SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.
Keywords
Metstatic Colon Cancer Treatment SarCNU NitrosureasReferences
- 1.National Cancer Institute of Canada (2002) Canadian cancer statistics 2003. Toronto, Canada, National Cancer Institute of CanadaGoogle Scholar
- 2.Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904–11Google Scholar
- 3.Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 343:905–14CrossRefPubMedGoogle Scholar
- 4.Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–0CrossRefPubMedGoogle Scholar
- 5.Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with Advanced Colorectal Cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–214CrossRefPubMedGoogle Scholar
- 6.Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim Results of a Phase III trial. J Clin Oncol 21:2059–069CrossRefPubMedGoogle Scholar
- 7.Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–37CrossRefPubMedGoogle Scholar
- 8.Noë AJ, Malapetsa A, Panasci LC (1993) Transport of (2-chloroethyl) 3-sarcosinamide-1-nitrosourea human glioma cell line SK-MG-1 is mediated by an epinephrine sensitive carrier system. Mol Pharmcol 44:204–09Google Scholar
- 9.Noë AJ, Malapetsa A, Panasci LC (1994) Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SK-1 correlates with differential transport kinetics. Cancer Res 54:1491–496PubMedGoogle Scholar
- 10.Panasci LC, Marcantonio D, Noë AJ (1996) SarCNU (2-chloroethyl-3-sarcinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake carrier, which mediated increased cytotoxicity. Cancer Chem Pharmacol 37:505–08CrossRefGoogle Scholar
- 11.Weinstein A, Duner-West M, Nelson D et al (1986) Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Tret Rep 70:943–46Google Scholar
- 12.Horton J, Mittleman A, Taylor SG (1975) Phase II trials with procarbazine (nsc-77213), streptozotocin (nsc-85998), 6-thioguanine (nsc-752), and CCNU (nsc-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep 59:333–40PubMedGoogle Scholar
- 13.Rubin J, Schott AJ, O’Connell MJ, et al. (1984) A Phase II study of the combination 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphoacetyl)-1-aspartate (PALA) in patients with advanced large bowel cancer. Am J Clin Oncol 7:523–;25CrossRefPubMedGoogle Scholar
- 14.Marcantonio O, Panasci LC, Hollingshead MG et al (1997) 2-chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhance antitumour activity against human glioma xenografts. Cancer Res 57:3895–;898PubMedGoogle Scholar
- 15.Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E (2003) SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. J Clin Oncol 21:232–;0CrossRefPubMedGoogle Scholar
- 16.Fleming TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143–;51CrossRefPubMedGoogle Scholar